期刊文献+

瑞舒伐他汀对慢性心力衰竭合并肾功能不全患者的疗效观察 被引量:10

The effects of Rosuvastatin in patients with chronic heart failure complicated with chronic renal dysfunction
下载PDF
导出
摘要 目的 观察瑞舒伐他汀治疗慢性心力衰竭合并肾功能不全的临床疗效.方法 回顾性分析2010年2月至2013年2月我院住院治疗的72例慢性心力衰竭合并肾功能不全患者的临床记录资料,所有患者均给予心力衰竭基础治疗,给予瑞舒伐他汀的患者作为治疗组,未给予的患者作为对照组.比较治疗6月后两组患者心功能和肾功能的变化.结果 治疗6个月后,治疗组心功能改善的总有效率显著高于对照组(P<0.05);左室射血分数较治疗前明显增高(P<0.05),左室舒张末期内径、左室收缩末期内径较治疗前缩小(P<0.05),且均优于对照组(P<0.05);血尿素氮、肌酐、β2-微球蛋白较对照组明显降低(P<0.05).结论 在常规抗心衰治疗的基础上联合使用瑞舒伐他汀,可以改善慢性心力衰竭患者的心功能及肾功能. Objective To observe the effects of Rosuvastatin in patients with chronic heart failure complicated with chronic renal dysfunction.Methods The clinical dataof 72 cases with chronic heart failure complicated with chronic renal dysfunction were retrospective analyzedin our hospitalfrom 2010 February to 2013 February.The cardiac function and renal function were compared after 3 months therapy between two groups.All patients were given basic treatment for heart failure.Cases given Rosuvastatin were as treatment group,while cases with no Rosuvastatin were as control group.Results After 3 months,the overall efficiency of heart function improved in significantly higher than that of the control group (P<0.05).After 3 months of carvidilol therapy left ventricular ejection fraction improved(P<0.05),while the Iefi ventricular end-diastolic dimension and left ventricular end-systolic dimension were decreased significantly in treatment group (P<0.05).The blood urea nitrogen,serum creatinine and blood β2-microglobulin(P<0.05).All of these results in treatment group were better than those in control group (P<0.05).Condusion Rosuvastatin treatment of chronic heart failure with renal insufficiency significantly,can significantly improve cardiac function and renal function,worthy of popularization.
出处 《中国心血管病研究》 CAS 2014年第7期647-650,共4页 Chinese Journal of Cardiovascular Research
关键词 瑞舒伐他汀 慢性心力衰竭 肾功能不全 Rosuvastatin Chronic heart failure Renal function
  • 相关文献

参考文献18

  • 1张林虎,苏庆丰,张晶晶,张志霞,郭明媚,李敏,杨靖,杨帆,张虹.瑞舒伐他汀对扩张型心肌病伴CHF病人心功能和超敏C反应蛋白的影响[J].中西医结合心脑血管病杂志,2012,10(6):666-668. 被引量:4
  • 2Go AS, Yang J, Ackerson LM, et al. Hemoglobin level, chonic kidney disease, and the risks of death aand hospitalization in adults with chonic heart failure:the Anemia in chonic Heart Failure : Outcomes and Resource Utilization (ANCHOR)Study. Circulation, 2006,113 : 2713-2723.
  • 3Amsalom Y, Garry M, Schwartz K, et al. Prevalence and significance of unrecognized renal in sufficiency in patients with heart failure. Eur Heart J,2008,29:1029-1036.
  • 4Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation, 2006,113 : 671-678.
  • 5李妮妮,张玉东.他汀类药物在慢性心力衰竭患者中的应用现状[J].中国心血管病研究,2008,6(5):394-396. 被引量:8
  • 6段慧.慢性心力衰竭合并肾功能不全住院患者270例临床分析[J].中国心血管病研究,2012,10(3):208-210. 被引量:7
  • 7McClellan WM, Langston RD, Presley R. Medicare patient with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease. J Am Soc Nephrol,2004,15: 1912-1919.
  • 8Cohen N, Gorelik O, Moznino-Sarafian D, et al. Renal dysfunction in congestive heart failure,pathophysiological and prognostic significance. Clin Ncphrol, 2004,61 : 177-184.
  • 9McAlister FA, Ezekowitz J, Tonelli M, et al. Renal in Sufficiency and heart failure : prognostic and therapeutic implications froma prospective cohortstudy. Circulation, 2004,109:1004-1009.
  • 10金争鸣,胡晓晟,陈君柱,胡申江,张芙荣.慢性心力衰竭患者早期肾损害的临床研究[J].中华内科杂志,2005,44(4):262-264. 被引量:42

二级参考文献100

  • 1杨水祥,胡大一.心力衰竭的新机制和新策略研究进展[J].中国心血管病研究,2005,3(6):403-405. 被引量:53
  • 2高金库,何书静,张明.强化降脂对急性冠脉综合征PCI患者远期疗效的影响[J].心血管康复医学杂志,2005,14(3):219-219. 被引量:4
  • 3全国eGFR课题协作组.MDRD方程在我国慢性肾脏病患者中的改良和评估[J].中华肾脏病杂志,2006,22(10):589-595. 被引量:702
  • 4冯绮莹,冯明华,何运平,陈思,梁文栋,罗承锋,刘世明.肾功能不全对充血性心力衰竭患者预后的影响[J].广东医学,2007,28(1):117-119. 被引量:4
  • 5[2]Bauersachs J,Galuppo P,Fraccarollo D,et al.Improvement of left ventricular remodeling and function by hydroxymethylglutaral coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction.Circulation,2001,104:982-985.
  • 6[3]Lou JD,Zhang WW,Zhang GP,et al.Simvastetin prevents angiotensin Ⅱ-induced cardiac alteration and oxidative stress.Hypertension,2002,40:142-147.
  • 7[4]Pliquett RU,Cornish KG,Peuler JD,et al.Simvastatin normalizes autonomic nearal control in experimental heart failure.Circulation,2003,107:2493-2498.
  • 8[5]Dichtl W,Dulak J,Frick M,et al.HMG-CoA reductase inhition regulate inflammatory transciption factors in human endothelial and vascular smooth muscle cells.Arterioscler Thromb Vase Bid,2003,23:58-63.
  • 9[6]Wojnicz R,Wilczek K,Nowalany-Kozielska E,et al.Usefulness of atorvastatin in pafiantswith heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol level.Am J Cardiol 2006,97:899-904.
  • 10[7]Ortegu M,Bustos C,Hemander-Presa MA,et al.Atovastatin reduces NF2KB activation and ehemokine exp ression in vascular smooth muscle cells and monomuclear cells.Atheresclerosis,1999,147:253-261.

共引文献201

同被引文献75

  • 1剡冬冬,马凌,张卫泽,王菲,郭文韵,蔡小庆,史亮.瑞舒伐他汀对慢性心力衰竭合并阵发性心房颤动的疗效观察[J].中国动脉硬化杂志,2015,23(4):407-410. 被引量:36
  • 2吴淼.瑞舒伐他汀改善冠心病合并肾功能不全患者的肾功能[C]//岭南心血管病杂志编辑部.第14届中国南方国际心血管病学术会议论文集.广州,2012:86-86.
  • 3Walczak-Jedrzejowska R,Wolski JK,Slowikowska-Hilczer J.The role of oxidative stress and antioxidants in male fertility[J].Cent European J Urol,2013,66(1):60,7.
  • 4Hage FG,Venkataraman R,Zogbbi GJ,et al.The scope of coronary heart disease in patients with chronic kidney disease[J].J Am Coll Cardiol,2009,53(23):2129-2140.
  • 5Toth PP.An update on the benefits and risks of rosuvastatin therapy[J].Postgrad Med,2014,126(2):7-17.
  • 6Alnouri F, Wood D, Kotseva K, et al.Which statin worked best to achieve lipid level targets in a European registry? A post-hoc analysis of the EUROASPIRE IIl for coronary heart disease patients [ J]. J Saudi Heart Assoc, 2014,26 (4) : 183-91.
  • 7Rogge BP, Cramariuc D, Ionnebakken MT, et al. Effect of overweight and obesity on cardiovascular events in asympto- matic aortic stenosis: a SEAS substudy (Simvastatin Ezetimibe in Aortic Stenosis)[ J]. J Am Coll Cardiol, 2013, 62 (18) : 1683-1690.
  • 8Har R, Scholey JW, Daneman D, et al.The effect of renal hy- perfihration on urinary inflammatory cytokines/chemokines in patients with uncomplicated type 1 diabetes metlitus [ J ]. Diabetologia, 2013,56 (5) : 1166-1173.
  • 9Abe M, Maruyama N, Okada K, et al. Effects of lipid- lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy [ J ]. J Atheroscler Thromb, 2011,18 ( 11 ) : 1018-1028.
  • 10Hong YJ, Jeong MH, Choi YH, et al. Usual dose of simvas- tatin does not inhibit plaque progression and lumen loss at the peri-stent reference segments after bare-metal stent im- plantation: a serial intravascular ultrasound analysis[ J]. Ko- rean J Intern Med, 2010, 25(4) :356-363.

引证文献10

二级引证文献65

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部